Convergent
Engineering, Inc. is developing signal processing algorithms and
techniques for breath-based medical diagnostic applications. They
have successfully developed data filters and signal processing
algorithms that reduce sensor variability and have shown positive
results in studies aimed at detecting propofol, a short-acting
intravenous anesthetic agent, in the breath and blood of
anesthetized animals.
The
company is currently in the process of fabricating a prototype
propofol monitoring device. This device is expected to be a
significant improvement over current propofol monitoring methods
and is targeted towards hospital-based anesthesiologists and
surgeons, as well as office-based dentists, orthodontists and
plastic surgeons.
Convergent
Engineering, Inc is partnering with Biocatalyst for
commercialization of its propofol monitoring device. Biocatalyst
specializes in accelerating commercialization of science-based
technologies. They expect a revenue stream starting in 2008. Much
of Convergent Engineering’s success has been made possible by
grants from the National Science Foundation and National
Institutes of Health.
